Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

HLA-B*15:02 is associated with anemia in patients with chronic hepatitis C treated with pegylated interferon-α and ribavirin.

Tseng CW, Hsieh YH, Chang CK, Lai NS, Hung TH, Wu SF, Tseng KC.

Tissue Antigens. 2012 Nov;80(5):424-30. doi: 10.1111/j.1399-0039.2012.01956.x. Epub 2012 Aug 30.

PMID:
22931407
2.

Prognostic effect of human leukocyte antigen class I and II alleles on chronic hepatitis C patients treated by pegylated interferon-alfa plus ribavirin in Taiwan.

Tseng KC, Chang CK, Chou AL, Hsieh YH, Tseng CA, Lai NS.

Hepatogastroenterology. 2010 May-Jun;57(99-100):456-61.

PMID:
20698208
3.

Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.

Di Marco V, Calvaruso V, Grimaudo S, Ferraro D, Pipitone RM, Di Stefano R, Craxì A.

J Viral Hepat. 2013 Feb;20(2):113-21. doi: 10.1111/j.1365-2893.2012.01637.x. Epub 2012 Jul 25.

PMID:
23301546
4.

Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin.

Balan V, Schwartz D, Wu GY, Muir AJ, Ghalib R, Jackson J, Keeffe EB, Rossaro L, Burnett A, Goon BL, Bowers PJ, Leitz GJ; HCV Natural History Study Group.

Am J Gastroenterol. 2005 Feb;100(2):299-307.

PMID:
15667486
5.

Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-α.

Hu CC, Weng CH, Lin CL, Tien HC, Kuo YL, Chien CH, Yen CL, Lin CY, Chien RN.

Ren Fail. 2012;34(4):429-34. doi: 10.3109/0886022X.2011.650562. Epub 2012 Jan 23.

PMID:
22264026
6.

Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients.

Ahmed WH, Furusyo N, Zaky S, Eldin AS, Aboalam H, Ogawa E, Murata M, Hayashi J.

World J Gastroenterol. 2013 Mar 7;19(9):1387-95. doi: 10.3748/wjg.v19.i9.1387.

7.
8.
9.

Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.

Mira JA, López-Cortés LF, Merino D, Arizcorreta-Yarza A, Rivero A, Collado A, Ríos-Villegas MJ, González-Serrano M, Torres-Tortoso M, Macías J, Valera-Bestard B, Fernández-Fuertes E, Girón-González JA, Lozano F, Pineda JA; Grupo para el Estudio de las Hepatitis Viricas de la Sociedad Andaluza de Enfermedades Infecciosas.

Antivir Ther. 2007;12(8):1225-35.

PMID:
18240862
10.

Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.

Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.

J Hepatol. 2013 Oct;59(4):667-74. doi: 10.1016/j.jhep.2013.05.017. Epub 2013 May 23.

PMID:
23707372
11.

Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.

Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, Herrine SK, Harrison SA, Poordad FF, Koury K, Deng W, Noviello S, Pedicone LD, Brass CA, Albrecht JK, McHutchison JG; IDEAL Study Team.

Gastroenterology. 2010 Nov;139(5):1602-11, 1611.e1. doi: 10.1053/j.gastro.2010.07.059. Epub 2010 Aug 16.

PMID:
20723545
12.

Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.

Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM; SPRINT-2 Trial Investigators.

Hepatology. 2013 Mar;57(3):974-84. doi: 10.1002/hep.26096. Epub 2013 Feb 11.

PMID:
23081753
13.

Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.

Pontali E, Angeli E, Cattelan AM, Maida I, Nasta P, Verucchi G, Caputo A, Iannacone C, Puoti M.

Antivir Ther. 2015;20(1):39-48. doi: 10.3851/IMP2781. Epub 2014 May 15.

PMID:
24831457
14.

[Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia].

Božić M, Bojović K, Fabri M, Nožić D, Trkulja B, Milošević I.

Srp Arh Celok Lek. 2012 Jul-Aug;140(7-8):448-55. Serbian.

15.

A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.

Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC Jr, Esposito SP, Brown RS Jr, Bräu N, Klion FM, Tobias H, Bini EJ, Brodsky N, Cerulli MA, Aytaman A, Gardner PW, Geders JM, Spivack JE, Rahmin MG, Berman DH, Ehrlich J, Russo MW, Chait M, Rovner D, Edlin BR.

Am J Gastroenterol. 2005 Nov;100(11):2453-62.

PMID:
16279900
16.

Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response.

Falasca K, Ucciferri C, Mancino P, Gorgoretti V, Pizzigallo E, Vecchiet J.

J Med Virol. 2010 Jan;82(1):49-56. doi: 10.1002/jmv.21657.

PMID:
19950239
17.

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study.

Silva GF, Villela-Nogueira CA, Mello CE, Soares EC, Coelho HS, Ferreira PR, Ruiz FJ; Brazilian HCV-Related Advanced Fibrosis Study Group.

Braz J Infect Dis. 2014 Jan-Feb;18(1):48-52. doi: 10.1016/j.bjid.2013.05.007. Epub 2013 Sep 20.

18.

The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study.

Ferreira PR, Silva MH, Brandão-Melo CE, Rezende RE, Gonzalez M, Reuter T, Urbaez JD, Gianini RJ, Martinelli A, Mendes-Correa MC.

Braz J Infect Dis. 2015 Jan-Feb;19(1):15-22. doi: 10.1016/j.bjid.2014.08.002. Epub 2014 Sep 1.

19.

Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.

Shoeb D, Dearden J, Weatherall A, Bargery C, Moreea S, Alam S, White E, Vila X, Freshwater D, Ryder S, Mills PR, Alexander GJ, Forton D, Foster GR.

J Hepatol. 2014 Apr;60(4):699-705. doi: 10.1016/j.jhep.2013.11.011. Epub 2013 Nov 26.

PMID:
24291239
20.

Natural history of anemia associated with interferon/ribavirin therapy for patients with HIV/HCV coinfection.

Henry DH, Slim J, Lamarca A, Bowers P, Leitz G; HIV/HCV Coinfection Natural History Study Group.

AIDS Res Hum Retroviruses. 2007 Jan;23(1):1-9.

PMID:
17263626

Supplemental Content

Support Center